Australia markets closed

Chugai Pharmaceutical Co., Ltd. (CHGCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
40.400.00 (0.00%)
As of 12:03PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close40.40
Open40.40
BidN/A x N/A
AskN/A x N/A
Day's range40.40 - 40.40
52-week range40.00 - 124.75
Volume1,600
Avg. volume451
Market cap64.303B
Beta (5Y monthly)0.70
PE ratio (TTM)34.09
EPS (TTM)1.18
Earnings dateN/A
Forward dividend & yield0.57 (1.41%)
Ex-dividend date29 Jun 2021
1y target estN/A
  • Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Business Wire

    Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obtained an import drug license from the Taiwan Food and Drug Administration (TFDA) for Chugai’s Enspryng® for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent over 12 years old patients who are anti-aquaporin-4 (AQP4) antibody positive.

  • New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Business Wire

    New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced the presentation of new Enspryng® (generic name: satralizumab [genetical recombination]) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MS Virtual 2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy and safety data on the continued effect of Enspryng on reducing the risk of NMOSD relapse as well as its benefit-risk profile. Enspryng is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai.

  • Chugai’s Enspryng (Satralizumab) Receives Regulatory Approval from FDA for Neuromyelitis Optica Spectrum Disorder
    Business Wire

    Chugai’s Enspryng (Satralizumab) Receives Regulatory Approval from FDA for Neuromyelitis Optica Spectrum Disorder

    Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has approved the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, Enspryng™ (US generic name: satralizumab-mwge) (hereafter, Enspryng) created by Chugai for the treatment of adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD). Enspryng is administered subcutaneously every four weeks**. Enspryng was granted Breakthrough Therapy Designation in December 2018 and the US Biologics License Application (BLA) was filed in August 2019 by Genentech Inc., a member of Roche Group.